Zymeworks, Inc. (ZYME)
28.77
+0.10
(+0.35%)
USD |
NASDAQ |
Aug 24, 16:00
29.00
+0.23
(+0.80%)
After-Hours: 20:00
Zymeworks EPS Diluted (Quarterly) : -0.6168 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.6168 |
| March 31, 2026 | -0.592 |
| December 31, 2025 | -0.547 |
| September 30, 2025 | -0.2587 |
| June 30, 2025 | 0.0299 |
| March 31, 2025 | -0.3033 |
| December 31, 2024 | -0.3148 |
| September 30, 2024 | -0.3921 |
| June 30, 2024 | -0.4933 |
| March 31, 2024 | -0.4179 |
| December 31, 2023 | -0.2045 |
| September 30, 2023 | -0.4065 |
| June 30, 2023 | -0.7603 |
| March 31, 2023 | -0.3649 |
| December 31, 2022 | 4.648 |
| September 30, 2022 | -0.7197 |
| June 30, 2022 | -0.9739 |
| March 31, 2022 | -1.183 |
| December 31, 2021 | -0.8396 |
| September 30, 2021 | -1.173 |
| June 30, 2021 | -1.313 |
| March 31, 2021 | -0.8681 |
| December 31, 2020 | -0.741 |
| September 30, 2020 | -1.426 |
| June 30, 2020 | -0.7671 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.6395 |
| December 31, 2019 | -1.657 |
| September 30, 2019 | -0.7015 |
| June 30, 2019 | -0.8855 |
| March 31, 2019 | -0.426 |
| December 31, 2018 | 0.2899 |
| September 30, 2018 | -0.5867 |
| June 30, 2018 | -0.22 |
| March 31, 2018 | -0.83 |
| December 31, 2017 | 1.28 |
| September 30, 2017 | -0.65 |
| June 30, 2017 | -0.63 |
| March 31, 2017 | -1.21 |
| December 31, 2016 | -0.4405 |
| September 30, 2016 | -0.4843 |
| June 30, 2016 | -0.29 |
| March 31, 2016 | -0.1059 |
| December 31, 2015 | -0.3105 |
| September 30, 2015 | -0.227 |
| June 30, 2015 | -0.1765 |
| March 31, 2015 | -0.0348 |
| December 31, 2014 | -0.1259 |
| September 30, 2014 | -0.1373 |
| June 30, 2014 | -0.1348 |
| March 31, 2014 | -0.1076 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Theravance Biopharma, Inc. | -0.1142 |
| BridgeBio Pharma, Inc. | -0.7775 |
| Aprea Therapeutics, Inc. | -0.0671 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -45.02M |
| Revenue (Quarterly) | 4.59M |
| Total Expenses (Quarterly) | 49.61M |
| Enterprise Value | 2.068B |
| Gross Profit Margin (Quarterly) | 57.43% |
| Profit Margin (Quarterly) | -980.8% |
| Earnings Yield | -7.00% |
| Normalized Earnings Yield | -6.992 |